A pleasure to talk to Alicia Morgans, MD, MPH (who is due in Aus 🇦🇺🦘🐨 now!) and UroToday.com about #radiotherapy in kidney cancer ❤️. See you soon at Peter Mac Cancer Centre! GU Cast | Urology podcast! #radonc

Excellent talk ⁦Dr. David Palma⁩ at #estro2024 on pragmatic design of clinical trial of reradiation for lung cancer . Linear curve of previous dose forgiveness with plateau at 5 years ⁦Shankar Siva⁩

Drew Moghanaki 🐕 Gerry Hanna Stanford Medicine Shankar Siva Nikki P SABR Bill Loo MD PhD ⚡️☢️ Clive Peedell Corinne Faivre-Finn 💙 Jolyne O'Hare 💙 Cathryn Crockett thegreenjournal.com/article/S0167-…

The manuscript is already published here. We can certainly look deeper into how the pain is resolved, however.

Continuing at #ESTRO24 lung mini oral Lucas Vitzthum presents analysis of Stanford Medicine iSABR study chest wall toxicity

➡️ Overall rates of chest wall pain were modest and low grade in nature
➡️ D2cc and V11Gy are correlated with rates of any grade toxicity

SBRT won the debate on nodal oligorecurrences at #ESTRO24 with 61% of the votes! This is a clearly different opinion as compared to the #APCCC24 , which has a more mixed audience voting, where only 3% would go for SBRT!

It was one year ago when I presented for the first time our Consensus at ESTRO and now I'm back presenting the final pubblication on The Lancet Oncology! Such a great journey and experience🤩! #oligometastaticRCC

Jeff Ryckman Henning Willers, MD Drew Moghanaki 🐕 Laura Dawson Shankar Siva Jake Scott Florian J. Fintelmann Since you mentioned single fraction… 😎

I’m presenting feasibility/acute toxicity outcomes of our multi-center SMART ONE trial at #ESTRO24 on Sunday

0.35T MRL, 25-40 Gy x 1

~1/3 lung, ~2/3 liver, adrenal, abdominal/pelvic LN, pancreas

~1/2 online adapted

🔥🔥 plans!

“The TIME Magazine 100 List for Healthcare? That’s cool & all, and I’m happy for Tom Powles, but I personally have always been after this shiny piece of metal …”

Behold — the Uromigos cup.

#UromigosLive24
#TeamLA : Tanya Dorff Petros Grivas
Uromigos.org

Generally a fan of #EAU #ESTRO etc guidelines. But curious why focal RT boost of tumor gets “weak” rating and ePLND gets “strong” 🤔

Only one of these has phase 3 RCT evidence of ⬇️ recurrence, ⬆️nodal/distant MFS, w/o toxicity increase.

Reconsider for 2025? ESTRO European Association of Urology (EAU)

50-day free link to our work here -
➡️ authors.elsevier.com/c/1j02A5EIIgPd…

The Lancet Oncology #radonc #kcsm . Peter Mac Radiation Oncology Sandro Porceddu

OLIGOPELVIS and the “All You Can Eat” Strategy for Oligorecurrent Nodal Prostate Cancer: Are We Already Full? ⁦Piet Ost⁩ ⁦Shankar Siva⁩ ⁦Supiot Stéphane⁩ ⁦Paul Sargos⁩ sciencedirect.com/science/articl…

We will see if our “experts” are doing the right thing. Although I still love Shankar Siva “eat, sleep, SABR, repeat!” So what is the correct endpoint for SABR vs whole pelvis.

Advancements in cutting-edge SABR therapy for oligometastatic #KidneyCancer . Shankar Siva Peter Mac Cancer Centre joins Alicia Morgans, MD, MPH Dana-Farber to discuss the innovative use of this therapy and its effectiveness in achieving local control > bit.ly/3WbPbyL

📢European Association of Urology (EAU) interview with Phillip Pierorazio about the role of SABR for primary #kidneycancer . Some penetrating questions prompted by FASTRACK II trial;
➡️ What do you counsel patients about long-term complications?
➡️ Is surgery possible after #radonc ?
shorturl.at/blzKL
#kcsm

Elliot Servais, MD, FACS It's also noteworthy to add this table to the discussion

A nationwide Dutch study (ESLUNG) demonstrates similar OS for stage I NSCLC treated with Lobectomy or SABR (HR 0.89, 95 % CI 0.65–1.20). #radonc #CSP2005 sciencedirect.com/science/articl…

Check it out!!! 😃

Clinical-research fellowships in radiation oncology at Peter Mac Cancer Centre! 🇦🇺

Apply here ➡️ careers.petermac.org/job/MELBOURNE-…

Just Out in the RED journal ASTRO 🇺🇸

The POP-RT trial 🇮🇳found that whole pelvic radiotherapy ☢️for high/very high-risk #ProstateCancer :

➡️resulted in comparable long-term urinary toxicity and quality of life to prostate-only radiotherapy, with no identified significant